Chao Lyu discusses the final efficacy and safety results from the NEOS trial, demonstrating the benefits of osimertinib for EGFR-mutated resectable stage II–IIIB lung adenocarcinoma in the neoadjuvant setting (4:03).
Chao Lyu discusses the final efficacy and safety results from the NEOS trial, demonstrating the benefits of osimertinib for EGFR-mutated resectable stage II–IIIB lung adenocarcinoma in the neoadjuvant setting (4:03).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Deputy Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.
